Trial results show statin drug does not slow Parkinson's
Simvastatin is a drug already used to lower cholesterol, and prevent heart attacks and strokes. Initial results from a major clinical trial show it doesn't have potential to slow the progression of Parkinson's as previously hoped.
Research shows bad dreams could predict future memory and thinking problems
Researchers in Portugal have discovered that the content of dreams, particularly those with negative emotions, may predict long-term cognitive decline in people with Parkinson’s.
Link found between diabetes and increased Parkinson’s risk
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
Parkinson’s UK commit further funding to develop drugs that protect mitochondria
We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
How have coronavirus (COVID-19) restrictions impacted people affected by Parkinson’s?
With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.
Researchers identify key player in genetic Parkinson’s
A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
Cannabis extract may hold key to stop pain in Parkinson's
Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.
Potential treatment for dyskinesia in Parkinson’s
Results from a one-year project, funded through the Parkinson’s Virtual Biotech, suggest that NLX-112 has potential as a future treatment for reducing dyskinesia and improving movement symptoms of Parkinson’s.
Initial results from CDNF clinical trial announced
Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.